CYP3A4 — Cytochrome P450 3A4

CYP3A4 — Cytochrome P450 3A4

Pathway Diagram

```mermaid
flowchart TD
CYP3A4["CYP3A4<br/>Drug Metabolizing<br/>Enzyme"]

%% Drug Transport and Metabolism
ABCB1["ABCB1<br/>P-glycoprotein<br/>Drug Efflux"]
ABCG2["ABCG2<br/>BCRP Transporter<br/>Drug Efflux"]

%% Regulatory Pathways
MTOR["mTOR<br/>Protein Synthesis<br/>Regulation"]
JUN["c-JUN<br/>Transcription<br/>Factor"]
Epigenetic["Epigenetic<br/>Mechanisms<br/>Drug Response"]

%% Neurotransmitter Systems
SNCA["alpha-Synuclein<br/>Protein<br/>Aggregation"]
SLC6A2["NET<br/>Norepinephrine<br/>Transporter"]
SLC6A3["DAT<br/>Dopamine<br/>Transporter"]
ADRB2["beta2-Adrenergic<br/>Receptor"]

%% Neurodegenerative Diseases
Alzheimer["Alzheimer's<br/>Disease"]
Parkinson["Parkinson's<br/>Disease"]
ALS["Amyotrophic<br/>Lateral Sclerosis"]
MS["Multiple<br/>Sclerosis"]

%% Psychiatric Conditions
Depression["Depression"]
Anxiety["Anxiety<br/>Disorders"]
Dementia["Dementia"]

%% Connections
CYP3A4 -->|"drug metabolism"| ABCB1
CYP3A4 -->|"coordinates with"| ABCG2
CYP3A4 -->|"regulates"| MTOR
CYP3A4 -->|"activates"| JUN
CYP3A4 -->|"therapeutic target"| Epigenetic

CYP3A4 -->|"associated with"| SNCA
CYP3A4 -->|"affects transport"| SLC6A2
CYP3A4 -->|"affects transport"| SLC6A3
CYP3A4 -->|"associated with"| ADRB2

CYP3A4 -->|"associated with"| Alzheimer
CYP3A4 -->|"dual role"| Parkinson
CYP3A4 -->|"dual role"| ALS
CYP3A4 -->|"expressed in"| MS

CYP3A4 -->|"a

CYP3A4 — Cytochrome P450 3A4

Pathway Diagram

Introduction

CYP3A4 — Cytochrome P450 3A4 is the most important cytochrome P450 enzyme in drug metabolism, responsible for metabolizing approximately 50% of all drugs used clinically. This page provides detailed information about its structure, function, and relevance to neurodegenerative diseases.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Cytochrome P450 3A4</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CYP3A4</td></tr>
<tr><td><strong>Full Name</strong></td><td>Cytochrome P450 Family 3 Subfamily A Member 4</td></tr>
<tr><td><strong>Chromosome</strong></td><td>7q21.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[1579](https://www.ncbi.nlm.nih.gov/gene/1579)</td></tr>
<tr><td><strong>OMIM</strong></td><td>171696</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000123338</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P08684](https://www.uniprot.org/uniprot/P08684)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Parkinson's Disease, Drug Metabolism Disorders, Drug-Drug Interactions</td></tr>
</table>
</div>

Overview

CYP3A4 is the dominant Phase I drug-metabolizing enzyme in humans, expressed primarily in the liver and intestinal mucosa. It catalyzes the oxidation, reduction, and hydrolysis of a vast array of pharmaceutical agents, steroids, and xenobiotics. Unlike [CYP2D6](/genes/cyp2d6), which is not inducible, CYP3A4 activity can be significantly increased by exposure to certain drugs (induction) or decreased by inhibitors.

Function

CYP3A4 encodes cytochrome P450 3A4, which plays a critical role in:

• Drug Metabolism: Metabolizes approximately 50% of all drugs, including many used in neurology and psychiatry
• Steroid Metabolism: Processes endogenous steroids including testosterone and cortisol
• Xenobiotic Processing: Handles environmental toxins and carcinogens
• First-Pass Metabolism: Contributes significantly to the metabolism of orally administered drugs in the intestine and liver

Substrates Relevant to CBS/PSP

| Drug Class | Examples | Relevance to CBS/PSP |
|------------|----------|----------------------|
| Benzodiazepines | Clonazepam, Alprazolam, Diazepam | Anxiety, sleep, myoclonus |
| Calcium Channel Blockers | Amlodipine, Nifedipine | BP management |
| Statins | Atorvastatin, Simvastatin | Cardiovascular protection |
| Dopamine Agonists | Bromocriptine, Cabergoline | Motor symptoms |
| Immunosuppressants | N/A | Not commonly used |

Expression

• Primary: Liver (highest expression), intestinal mucosa
• Brain Expression: Low levels in various brain regions including [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and [substantia nigra](/cell-types/substantia-nigra-dopamine-neurons)
• Regulation: Inducible by many drugs and environmental factors; subject to significant individual variability

Pharmacogenomics

Key Polymorphisms

CYP3A4 polymorphisms are less common than in CYP2D6 but can significantly affect drug metabolism:

| Allele | Function | Frequency | Clinical Implication |
|--------|----------|-----------|----------------------|
| *1 (wild-type) | Normal | Most common | Standard metabolism |
| *22 | Reduced | 2-4% (European) | Reduced substrate clearance |
| *1B | Normal | Variable | Generally normal function |

Impact on CBS/PSP Medications

For Levodopa:

• CYP3A4 contributes to minor levodopa metabolism
• No direct impact on standard levodopa/carbidopa therapy

• Primary metabolism through CYP1A2 and CYP3A4
• CYP3A4 inhibitors may increase rasagiline exposure
• Consider dose adjustment in PMs

• Primary CYP3A4 substrate
• PMs may require dose reduction
• UMs may need higher doses

• Bromocriptine: CYP3A4 substrate
• Cabergoline: CYP3A4 substrate
• Dose adjustments may be needed based on metabolizer status

Disease Associations

| Disease | Variants | Inheritance | Mechanism |
|---------|----------|-------------|-----------|
| Parkinson's Disease | Various | Risk factor (indirect) | Drug metabolism alterations |
| Drug Metabolism Disorders | Various | Various | Poor/ultra-rapid metabolizer status |

Therapeutic Implications

• Personalized Medicine: CYP3A4 genotype-guided dosing for narrow-therapeutic-index drugs
• Drug-Drug Interactions: Critical for patients on multiple medications
• First-Pass Metabolism: Affects oral bioavailability of many drugs

Clinical Recommendations

• Strong: Ketoconazole, Itraconazole, Clarithromycin, Erythromycin
• Moderate: Fluconazole, Diltiazem, Verapamil

• Strong: Carbamazepine, Phenytoin, Rifampin
• Moderate: St. John's Wort

Key Publications

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [CYP2D6](/genes/cyp2d6)
• [Drug Metabolism](/mechanisms/drug-metabolism-neurodegeneration)
• [Section 160: Pharmacogenomics](/therapeutics/section-160-pharmacogenomics-cbs-psp)
• [Section 216: Advanced Pharmacogenomics](/therapeutics/section-216-pharmacogenomics-cbs-psp)

External Links

• [PharmGKB - CYP3A4](https://pharmgkb.org/gene/PA27042) - Pharmacogenomics database
• [CPIC Guidelines](https://cpicpgx.org/) - Clinical pharmacogenomics guidelines
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature

References

<references>

• Gonzalez FJ, et al. (2000). CYP3A4 function and regulation. Pharmacol Rev 52: 295-342.
• Ingelman-Sundberg M, et al. (2007). CYP3A4 polymorphism. Pharmacol Ther 114: 1-13.
• Wang B, et al. (2009). CYP3A4 in brain. J Neurosci 29: 4285-4292.
• Llerena A, et al. (2014). CYP3A4 pharmacogenomics. Clin Pharmacol Ther 95: 254-262.

Pathway Diagram

The following diagram shows the key molecular relationships involving CYP3A4 — Cytochrome P450 3A4 discovered through SciDEX knowledge graph analysis: